Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood

Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to quantify hepatic fibrogenesis flux rates both directly in liver tissue and noninvasively in blood. Twenty‐one patients with suspected NAFLD ingested heavy water (2H2O, 50‐mL aliquots) two to three times daily for 3‐5 weeks prior to a clinically indicated liver biopsy. Liver collagen fractional synthesis rate (FSR) and plasma lumican FSR were measured based on 2H labeling using tandem mass spectrometry. Patients were classified by histology for fibrosis stage (F0‐F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis (NASH). Magnetic resonance elastography measurements of liver stiffness were also performed. Hepatic collagen FSR in NAFLD increased with advancing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibrosis score and liver stiffness) and correlated with hemoglobin A1C. In addition, plasma lumican FSR demonstrated a significant correlation with hepatic collagen FSR. Conclusion: Using a well‐characterized cohort of patients with biopsy‐proven NAFLD, this study demonstrates that hepatic scar in NASH is actively remodeled even in advanced fibrosis, a disease that is generally regarded as static and slowly progressive. Moreover, hepatic collagen FSR correlates with established risks for fibrotic disease progression in NASH, and plasma lumican FSR correlates with hepatic collagen FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis in humans. (Hepatology 2017;65:78‐88).

[1]  Lynne Pearce,et al.  Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[2]  J. C. Price,et al.  Circulating protein synthesis rates reveal skeletal muscle proteome dynamics. , 2015, The Journal of clinical investigation.

[3]  N. Schork,et al.  Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. , 2015, Gastroenterology.

[4]  Monjur Ahmed,et al.  Non-alcoholic fatty liver disease in 2015. , 2015, World journal of hepatology.

[5]  S. Subramaniam,et al.  Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study , 2015, Gut.

[6]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[7]  T. Angel,et al.  Turnover Rates of Hepatic Collagen and Circulating Collagen-Associated Proteins in Humans with Chronic Liver Disease , 2015, PloS one.

[8]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  D. Brenner,et al.  Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.

[10]  M. Neuman,et al.  Biomarkers in nonalcoholic fatty liver disease. , 2014, Canadian journal of gastroenterology & hepatology.

[11]  F. Eren,et al.  A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease , 2014, Scandinavian journal of gastroenterology.

[12]  Anthony Gamst,et al.  Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study , 2014, Hepatology.

[13]  S. Friedman,et al.  Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? , 2014, Antiviral research.

[14]  S. Turner,et al.  Proteomic Analysis of Altered Extracellular Matrix Turnover in Bleomycin-induced Pulmonary Fibrosis , 2014, Molecular & Cellular Proteomics.

[15]  Rohit Loomba,et al.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.

[16]  Richard L Ehman,et al.  Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. , 2013, Radiology.

[17]  Rohit Loomba,et al.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. , 2013, Journal of diabetes and its complications.

[18]  R. Ehman,et al.  Magnetic resonance elastography of liver: Technique, analysis, and clinical applications , 2013, Journal of magnetic resonance imaging : JMRI.

[19]  S. Friedman,et al.  Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.

[20]  G. Gores,et al.  Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis , 2012, Laboratory Investigation.

[21]  V. Paradis,et al.  A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis , 2012, Hepatology.

[22]  D. Brenner,et al.  Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial , 2012, Hepatology.

[23]  D. Brenner,et al.  Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD , 2012, Alimentary pharmacology & therapeutics.

[24]  K. Clément,et al.  Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data , 2012, PloS one.

[25]  R. Ehman,et al.  Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. , 2011, Radiology.

[26]  D. Schuppan,et al.  Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. , 2011, Gastroenterology.

[27]  S. Sanderson,et al.  Differential expression of lumican and fatty acid binding protein‐1: New insights into the histologic spectrum of nonalcoholic fatty liver disease , 2009, Hepatology.

[28]  A. Manduca,et al.  Assessment of hepatic fibrosis with magnetic resonance elastography. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[30]  H. Skinner,et al.  Alcohol dependence syndrome: measurement and validation. , 1982, Journal of abnormal psychology.

[31]  T. Angel,et al.  Dynamic Proteomics: In Vivo Proteome-Wide Measurement of Protein Kinetics Using Metabolic Labeling. , 2015, Methods in enzymology.

[32]  J. C. Price,et al.  Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. , 2012, Analytical biochemistry.